Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 4, 2003, Pages 602-606

  Partridge, Ann H ^a   Wang, Philip S ^a   Winer, Eric P ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; DRUG EFFICACY; DRUG RESPONSE; ENDOMETRIUM CANCER; FEMALE; HUMAN; MASTECTOMY; MENOPAUSAL SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; MEDICAID; MIDDLE AGED; PATHOLOGY; TREATMENT REFUSAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; MEDICAID; MIDDLE AGED; NEW JERSEY; TAMOXIFEN; TREATMENT REFUSAL; UNITED STATES;

EID: 0037441639     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.071     Document Type: Article

References (47)

1. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
2. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
4. Love RR: Tamoxifen therapy in early breast cancer: Biology, efficacy and side effects. J Clin Oncol 7:803-815, 1989
5. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984
6. Van Leeuwen FE, Benraadt J, Coebergh JWW: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
7. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
8. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 88:1543-1549, 1996
9. NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer. Vol 17, No 4, Bethesda, MD, November 1-3, 2000, http://consensus.nih. gov/
10. Haynes RB, Taylor DW, Sackett DL: Compliance in Health Care. Baltimore, Johns Hopkins University Press, 1979
11. Love RR, Cameron L, Connell BL, et al: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151:1842-1847, 1991
12. Sackett DL, Haynes RB: Compliance with Therapeutic Regimens. Baltimore, Johns Hopkins University Press, 1976
13. Cooper JK, Love DW, Raffoul PR: Intentional prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc 30:329-333, 1982
14. Horwitz RI, Horwitz SM: Adherence to treatment and heath outcomes. Arch Intern Med 153:1863-1868, 1993
15. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer: Analyses at six years by Nolvadex Adjuvant Trial Organization. Lancet 1:836-840, 1985
16. Schumacher M, Bastert G, Bojar H, et al: Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. J Clin Oncol 12:2086-2093, 1994
17. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al: Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90:1461-1467, 1998
18. Waterhouse DM, Calzone KA, Mele C, et al: Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11:1189-1197, 1993
19. Leventhal H, Nerenz D, Leventhal E, et al: The behavioral dynamics of clinical trials. Prev Med 20:132-146, 1991
20. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
21. Steiner JF, Koepsell TD, Fihn SD, et al: A general method of compliance assessment using centralized pharmacy records: Description and validation. Med Care 26:814-823, 1988
22. Gurwitz JH, Glynn RJ, Monane M, et al: Treatment for glaucoma: Adherence by the elderly. Am J Public Health 83:711-716, 1993
23. Monane M, Bohn R, Gurwitz JH, et al: Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 154:433-437, 1994
24. Avorn J, Monette J, Lacour A, et al: Persistence of use of lipid-lowering medications: A cross-national study. J Am Med Assoc 279:1458-1462, 1998
25. Monane M, Bohn RL, Gurwitz JH, et al: Compliance with antihypertensive therapy among elderly Medicaid enrollees: The roles of age, gender, and race. Am J Public Health 86:1805-1808, 1996
26. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82:18-21, 1990
27. SAS Version 6.12. Cary, NC, SAS Institute, 1996
28. Roe CM, Motheral BR, Teitelbaum F, et al: Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 138:818-825, 1999
29. Partridge AH, Avorn J, Wang PS, et al: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661, 2002
30. Tormey DC, Simon RM, Lippman ME, et al: Evaluation of tamoxifen dose in advanced breast cancer: A progress report. Cancer Treat Rep 60:1451-1459, 1976
31. Decensi A, Gandini S, Guerrieri-Gonzaga A, et al: Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17:2633-2638, 1999
32. Balkrishnan R: Predictors of medication adherence in the elderly. Clin Ther 20:764-771, 1998
33. Ganz PA, Schag CC, Heinzich RL: The psychosocial impact of cancer on the elderly: A comparison with younger patients. J Am Geriatr Soc 33:429-435, 1985
34. Ganz PA: Breast cancer in older women: Quality-of-life considerations. Cancer Control 1:372-379, 1994
35. Wenzel LB, Fairclough DL, Brady MJ, et al: Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 86:1768-1774, 1999
36. Compas BE, Stoll MF, Thomsen AH, et al: Adjustment to breast cancer: Age-related differences in coping and emotional distress. Breast Cancer Res Treat 54:195-203, 1999
37. Haynes RB: A critical review of the "determinants" of patient compliance with therapeutic regimens, in Sackett DL, Haynes RB (eds): Compliance with Therapeutic Regimens. Baltimore, Johns Hopkins University Press, 1976, pp 26-39
38. Mandelblatt JS, Hadley J, Kerner JF, et al: Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physical influences. Cancer 89:561-573, 2000
39. Samet JM, Hunt WC, Farrow DC: Determinants of receiving breast-conserving surgery: The Surveillance, Epidemiology, and End Results Program, 1983-1986. Cancer 73:2344-2351, 1994
40. Cramer JA, Scheyer RD, Mattson RH: Compliance declines between clinic visits. Arch Intern Med 150:1509-1510, 1990
41. Morisky DE, DeMuth NM, Field-Fass M, et al: Evaluation of family health education to build social support for long-term control of high blood pressure. Health Educ Q 12:35-50, 1985
42. Chisholm MA, Vollenweider LJ, Mulloy LL, et al: Renal transplant patient compliance with free immunosuppressive medications. Transplantation 70:1240-1244, 2000
43. Choo PW, Rand CS, Inui TS, et al: Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 37:846-857, 1999
44. Bright RA, Avorn J, Everitt DE: Medicaid data as a resource for epidemiologic studies: Strengths and limitations. J Clin Epidemiol 42:937-945, 1989
45. Avorn J, Soumerai SB: Improving drug-therapy decisions through educational outreach: A randomized controlled trial of academically based "detailing". N Engl J Med 308:1457-1463, 1983
46. Ray WA, Griffin MR: Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 129:837-849, 1989
47. Fisher ES, Whaley FS, Krushat WM, et al: The accuracy of Medicare's hospital claims data: Progress has been made, but problems remain. Am J Public Health 82:243-248, 1992